Exane Derivatives Intercept Pharmaceuticals, Inc. Transaction History

Exane Derivatives

$157 Million
Q2 2022

A detailed history of Exane Derivatives transactions in Intercept Pharmaceuticals, Inc. stock. As of the latest transaction made, Exane Derivatives holds 6 shares of ICPT stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 6 -0.0%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Jan 22, 2020	SELL	$57.36 - $124.1 $216,878 - $469,222	-3,781 Reduced 99.84%	6 $0
Q2 2019 Jul 12, 2019	BUY	$77.77 - $120.68 $294,048 - $456,291	3,781 Added 63016.67%	3,787 $0
Q4 2018 Jan 31, 2019	SELL	$85.79 - $126.46 $85 - $126	-1 Reduced 14.29%	6 $0
Q1 2018 Apr 30, 2018	SELL	$52.72 - $67.25 $49,714 - $63,416	-943 Reduced 99.26%	7 $0
Q4 2017 Jan 29, 2018	SELL	$58.2 - $72.76 $240,191 - $300,280	-4,127 Reduced 81.29%	950 $0
Q3 2017 Oct 18, 2017	BUY	$57.01 - $118.75 $289,439 - $602,893	5,077	5,077 $0

Others Institutions Holding ICPT

# of Institutions

Shares Held

1.04M

Call Options Held

30K

Put Options Held

5.9K

View Full List

About INTERCEPT PHARMACEUTICALS, INC.

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

More about ICPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

News

Stay updated on Exane Derivatives with notifications on news.

Account

Exane Derivatives Intercept Pharmaceuticals, Inc. Transaction History